Clinical Trials Browser

Phase 2 × Medulloblastoma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all

NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Phase 2 Completed

39 enrolled 9 charts

CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

Phase 2 Withdrawn

Medulloblastoma, Meningioma, Neuroblastoma